Head of the Thoracic Group at Institut Gustave Roussy (IGR), Villejuif, FRANCE

President of the International Centre for Thoracic Cancers (CICT), a health cooperation group combining Gustave Roussy, the Marie-Lannelongue Hospital and the Paris Saint-Joseph Hospital.

Prof. Planchard’s primary research interests have focused on immunotherapy, genomic analysis and biomarkers and targeted treatments of lung cancers over the last 20 years of his career. He has been involved in more than 200 phase I, II and III clinical trials, with over 270 published articles. Highly Cited Researcher (clarivate) since 2020.

He has been directly involved in trial design, having been international coordinating investigator on trials in the field of thoracic tumours, with the aim to develop a long-term clinical research strategy based on molecular screening.

Prof. Planchard participated the latest european recommendations on the management of metastatic non-small-cell lung cancer (ESMO guidelines) and participated in many national and international conferences including ESMO (European Society for Medical Oncology), ELCC (European Lung Cancer Congress), ASCO (American Society of Clinical Oncology) and WCLC (World Conference of Long Cancer).

Prof. David Planchard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

ArriVent, AstraZeneca, Abbvie, BMS, Bohringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, GSK, Janssen, Medimmun, Merck, Mirati, Novartis, Novocure, Pfizer, Roche, Pierre Fabre, Sanofi-Aventis, Seagen, Taiho Pharma, Takeda